SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Cerrado

SectorSalud

115.5 1.49

Resumen

Variación precio

24h

Actual

Mínimo

113.8

Máximo

115.8

Métricas clave

By Trading Economics

Ingresos

215M

Ventas

785M

P/B

Media del Sector

31.236

57.333

Rentabilidad por dividendo

0.79

Margen de beneficio

11.32

Empleados

14,147

EBITDA

161M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+16.61% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.79%

2.63%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-117M

13B

Apertura anterior

114.01

Cierre anterior

115.5

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

BioMerieux Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 abr 2025, 08:49 UTC

Principales Movimientos del Mercado

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Comparación entre iguales

Cambio de precio

BioMerieux Esperado

Precio Objetivo

By TipRanks

16.61% repunte

Estimación a 12 meses

Media 133.17 EUR  16.61%

Máximo 140 EUR

Mínimo 127 EUR

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMerieux Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

113.8 / 118.9Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.